Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants

We aimed to provide in vitro data on the neutralization capacity of different monoclonal antibody (mAb) preparations against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) delta and omicron variant, respectively, and describe the in vivo RNA kinetics of coronavirus disease 2019 (CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Brehm, Thomas Theo, Pfefferle, Susanne, von Possel, Ronald, Karolyi, Mario, Zoufaly, Alexander, Wichmann, Dominic, Kobbe, Robin, Emmerich, Petra, Nörz, Dominik, Aepfelbacher, Martin, Schulze zur Wiesch, Julian, Addo, Marylyn M., Schmiedel, Stefan, Lütgehetmann, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347884/
https://www.ncbi.nlm.nih.gov/pubmed/35662058
http://dx.doi.org/10.1002/jmv.27916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347884/
https://www.ncbi.nlm.nih.gov/pubmed/35662058
http://dx.doi.org/10.1002/jmv.27916

Ejemplares similares